These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34646061)

  • 1. Computational Evaluation of Bioactive Compounds from
    Balogun TA; Ipinloju N; Abdullateef OT; Moses SI; Omoboyowa DA; James AC; Saibu OA; Akinyemi WF; Oni EA
    Cancer Inform; 2021; 20():11769351211049244. PubMed ID: 34646061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of phytochemicals from
    Yasmeen N; Ahmad Chaudhary A; K Niraj RR; Lakhawat SS; Sharma PK; Kumar V
    J Biomol Struct Dyn; 2023 Dec; ():1-43. PubMed ID: 38141177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemico-pharmacological evaluations of the dwarf elephant ear (
    Alam S; Richi FT; Hasnat H; Ahmed F; Emon NU; Uddin MJ; Rana GMM; Wang S; Yeasmin MS; Ahmed NU; Khan MS; Al Mamun A
    Front Pharmacol; 2024; 15():1428341. PubMed ID: 39193333
    [No Abstract]   [Full Text] [Related]  

  • 5. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
    Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
    Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potential HER2 inhibitors from
    Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
    J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational Evaluation of Azadirachta indica-Derived Bioactive Compounds as Potential Inhibitors of NLRP3 in the Treatment of Alzheimer's Disease.
    Ishabiyi FO; Ogidi JO; Olukade BA; Amorha CC; El-Sharkawy LY; Okolo CC; Adeniyi TM; Atasie NH; Ibrahim A; Balogun TA
    J Alzheimers Dis; 2023; 94(s1):S67-S85. PubMed ID: 36683510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational investigation of
    Yousaf MA; Anwer SA; Basheera S; Sivanandan S
    J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational evaluation of bioactive compounds from
    Dairo G; Ilesanmi A; Balogun T; Ward M; Soendergaard M; Determan J
    J Biomol Struct Dyn; 2023; 41(24):15610-15624. PubMed ID: 36935102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Exploration of Fluorocyclopentenyl-purines and-pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer.
    Abida Ejaz S; Sajjad Bilal M; Aziz M; Wani TA; Zargar S; Fayyaz A; Hassan S; Ahmed A; Al Kahtani HM; Siddique F
    Chem Biodivers; 2023 Dec; 20(12):e202301190. PubMed ID: 37963090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DFT, molecular docking and molecular dynamics simulation studies on some recent natural products revealing their EGFR tyrosine kinase inhibition potential.
    Erdogan T; Oguz Erdogan F
    J Biomol Struct Dyn; 2024 Apr; 42(6):2942-2956. PubMed ID: 37144731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for their Anti-EGFR Activity Against Tumor Angiogenesis.
    Shah AA; Ahmad S; Yadav MK; Raza K; Kamal MA; Akhtar S
    Curr Med Chem; 2024; 31(5):595-619. PubMed ID: 36892124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
    Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
    3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of
    Wu L; Wang Y; Wang X; Liao J; Dong H; Cai X; Wang Y; Gu HF
    Food Nutr Res; 2021; 65():. PubMed ID: 34908921
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.